GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

Sievers, P., Stichel, D., Sill, M., Schrimpf, D., Sturm, D., Selt, F., … Sahm, F. (2021, December 1). GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00401-021-02369-1